StrongBio has backgrounds we can't discredit him. Ok, he's gotten emotional, but he does have connections with large shareholders. I'd agree with SB that the deal ended up Cytrx with the short straw. A very short straw.
Aldox with 17 indications, we're talking well over 10 billion where some saying 17 billion in potential market plus the 7 year exclusive and 10 in EU. Because this is new and not generic, price can be 3x easily ok. NantCell was making off like a thief if you want to put it that way.
Cytrx being offered some 350 million and increasing double digit on STS but only mid to high single digit on all other indications. That's not the best deal for sure and that might be why they haven't filed with SEC yet is that there are internal disagreement and owners of the company want a better deal.
Come on, 17 billion potential market for 7 years exclusinve and continual sales beyond and we got offered 350 million plus increasing double digit on only on indication. When you know the true value and look at what you got offered, you'd probably say no to the deal as well lol.
So, delisting and all that worry is really not the biggest issue here. None the less it's a problem they need to deal with.
I am torn in between and will wait and see before deciding to load more or not. What we got here is a vary valuable product and it looks like the owners are trying to prevent the company from being ripped off.
News 
Market Data 
Discover 
AI
